Mentioned in ?
References in periodicals archive ?
These long-acting agents, whose extended half-lives allow for the convenience of once-weekly dosing, will most likely compete with vancomycin IV (Baxter/Eli Lilly; generics) and Cubist's Cubicin in the cSSSI/OM OPAT market.
We continue to articulate the clinical benefits of the drug for appropriate patients, and we are continuing to develop the story around the economic impact that CUBICIN can have in the hospital overall.
Although this study showed that Cubicin is an alternative for all S.
We had another strong year in 2012, driven in large measure by the continued growth of CUBICIN.
Michael Bonney, president and CEO of Cubist said, "In the midst of a deep recession, which has impacted the growth of many companies and stunted economic growth, Cubist has had another strong year supported by the performance of CUBICIN.
About CUBICIN CUBICIN[R] (daptomycin for injection) is approved in the U.
Bonney, president & CEO of Cubist, commented: "Based on twenty weeks of sales data since launch as well as recently completed market research, we now feel comfortable providing an expected range for CUBICIN sales this year.
also finds that ID specialists and PCPs have differential preferences for Cubist/Novartis/Merck's Cubicin and Pfizer's Zyvox, respectively, as their preferred anti-MRSA antibiotic brands.
The breadth of presentations at ICAAC shows how we are advancing science to not only inform the appropriate use of CUBICIN but also to discover and develop new antibiotics for serious and potentially life-threatening infections," said Steve Gilman, PhD, Chief Scientific Officer at Cubist Pharmaceuticals.
By year-end 2017, the Company expects CUBICIN will well-exceed $1 billion in U.
MRSA Infections are a Key Driver of Zyvox and Cubicin Usage, According to New Report from Arlington Medical Resources